46 completed, 10 unknown, 2 active not recruiting, 2 not yet recruiting. 65 Phase 2, 6 Phase 3, 2 Phase 1.
Follow Tinea: new trials by email Literature Review of Tinea trials Research Report on Tinea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of SKX-16 in Participants With Mild to Moderate Distal Subungual Onychomycosis SKX-16 (Luliconazole 10% Solution), Vehicle solution - Onychomycosis of Toenails | Phase 2 | Not yet recruiting | SATO Pharmaceutical Co., Ltd. | 204 | 2026-11-24 | 2026-11-10 |
| Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis Trichostatin A - Onychomycosis of Toenail | Phase 2 | Active not recruiting | Vanda Pharmaceuticals | 50 | 2025-05-05 | 2026-02-04 |
| Efficacy and Safety of Topical Amphotericin B Solution in Treatment of Resistant Tinea Capitis in Children 16 Years Old or Less we Follow up Cases Weekly up to 8 Weeks and Notice Improvement of Itching ,Scaling, and Hair Regrowth Then Fungal Culture Done to See if the Solution Working Amphotericine in liposome (Ambisome®) - Tinea Capitis | Phase 2 / Phase 3 | Active not recruiting | Sohag University | 30 | 2025-04-01 | 2025-05-20 |
| Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study 1% Tolnaftate Stick Formula A, 1% Tolnaftate Stick Formula B, 1% Tolnaftate Stick Formula C - Tinea Pedis | Phase 2 | Recruiting | Propedix, Inc. | 150 | 2024-12-30 | 2025-11-28 |
| Role of Oral Voriconazole in the Treatment of Resistant Dermatophyte Infections Voriconazole high dose, Voriconazole low dose - Dermatophyte Infection | Phase 2 | Not yet recruiting | Sheikh Zayed Medical College | 120 | 2024-11-15 | 2024-11-08 |
| A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis ATB1651-102- Cohort 1, ATB1651-102- Cohort 2, ATB1651-102- Cohort 3 - Onychomycosis | Phase 2 | Recruiting | AmtixBio Co., Ltd. | 120 | 2024-07-01 | 2025-02-19 |
| A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis DBI-001, DBI-002, Aqueous Gel - Onychomycosis | Phase 2 | Suspended | DermBiont, Inc. | 60 | 2023-11-01 | 2023-09-07 |
| Efficacy and Safety of Terbinafine and Itraconazole Terbinafine Tablets, Itraconazole - Tinea Corporis, Tinea Cruris | Phase 2 / Phase 3 | Unknown | Dhaka Medical College | 150 | 2023-05-01 | 2023-05-31 |
| Pilot Study of Swift Microwave Device for Onychomycosis Swift Microwave treatment - weekly x 4wks, Swift Microwave treatment - Every other week x 4wks, Swift Microwave treatment - Every other week x 24wks - Onychomycosis of Toenail | Phase 1 / Phase 2 | Completed | Mediprobe Research Inc. | 39 | 2023-03-27 | 2024-11-18 |
| A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis DBI-001 Gel, DBI-002 Gel, Aqueous Gel - Tinea Pedis | Phase 2 | Unknown | DermBiont, Inc. | 24 | 2022-09-08 | 2023-02-14 |
| To Evaluate Hallux Terbinafine Subungual Gel (HSG) in the Treatment of Onychomycosis Hallux Terbinafine Subungual Gel - Onychomycosis of Toenail | Phase 2 | Unknown | Hallux, Inc. | 35 | 2022-01-13 | 2023-08-07 |
| A Trial Involving Treatment of BB2603 in Subjects With Distal Subungual Onychomycosis of the Toenail BB2603-1, BB2603-3, BB2603-10 - Distal Subungual Onychomycosis, Fungal Infection | Phase 2 | Completed | Blueberry Therapeutics | 111 | 2021-03-22 | 2023-08-01 |
| Systemic Uptake of Diclofenac Sodium in Combination With Miconazole as Antifungal Nail Gel When Applied Daily With Monitoring of Hepatic and Renal Enzymes, and Serum Levels of Diclofenac 12 Hours After Application, and at 3 and 6 Months Study Antifungal Nail Gel Study - Tinea Unguium, Onychomycosis | Phase 2 | Unknown | William N Handelman | 30 | 2020-05-01 | 2020-04-10 |
| A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis UHE-103A1 cream, UHE-103A2 cream, UHE-103B cream - Tinea Pedis | Phase 2 | Completed | Therapeutics, Inc. | 240 | 2019-03-15 | 2021-10-28 |
| A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis Janthinobacterium lividum - Tinea Pedis | Phase 2 | Completed | DermBiont, Inc. | 12 | 2019-02-19 | 2025-06-17 |
| SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS TERBINAFINE HYDROCHLORIDE (1%), BUTENAFINE HYDROCHLORIDE (1%), Vehicle Control - Tinea Pedis | Phase 2 | Unknown | United Laboratories | 42 | 2019-01-02 | 2019-06-26 |
| Isotretinoin In Preventing Recurrences In Chronic Recurrent Dermatophytosis Isotretinoin, Terbinafine, Itraconazole 200 mg - Tinea | Phase 2 | Unknown | Post Graduate Institute of Medical Education and Research, Chandigarh | 100 | 2018-04-01 | 2018-05-01 |
| Three-Arm Trial of Novel Treatment for Tinea Pedis Experimental Drug SESC 01, Placebo, Terbinafine Hydrochloride - Tinea Pedis | Phase 2 | Completed | South End Skin Care | 90 | 2017-01-03 | 2017-10-06 |
| The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis CELEXT07, Penlac, vehicle solution - Onychomycosis | Phase 2 | Unknown | 9305-9954 Quebec Inc | 120 | 2016-11-01 | 2017-04-26 |
| Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis S2G6T-1, S2G6T-2, S2G6T-3 - Tinea Pedis | Phase 2 | Terminated | Sol-Gel Technologies, Ltd. | 283 | 2016-09-01 | 2020-11-18 |
Showing 20 of 65. Sign in to see all of them.
Onychomycosis (40) · Tinea Pedis (17) · Mycoses (3) · Tinea Capitis (3) · Tinea Cruris (3) · Dermatomycoses (2) · Anemia (1) · Cellulitis (1) · Communicable Diseases (1) · Foot Dermatoses (1) · Foot Diseases (1) · Helminthiasis (1) · Infections (1) · Pruritus (1)
Bacterial Infections and Mycoses (65) · Skin Diseases, Infectious (65) · Skin and Connective Tissue Diseases (65) · Infections (64) · Skin Diseases (64) · Dermatomycoses (63) · Mycoses (62) · Nail Diseases (40) · Pathological Conditions, Signs and Symptoms (18) · Signs and Symptoms (17) · Skin Manifestations (17) · Foot Dermatoses (16) · Foot Diseases (16) · Pruritus (16)
Terbinafine (8) · tavaborole (5) · Itraconazole (3) · 1-(2-(2,4-dichlorophenyl)-2-(4-(trifluoromethyl)benzyloxy)ethyl)-1H-imidazole (2) · BANG polymer gel (2) · Miconazole (2) · Nitric Oxide (2) · VT-1161 (2) · Albendazole (1) · Ciclopirox (1) · Diclofenac (1) · Econazole (1) · Exercise (1) · Isotretinoin (1) · Ketoconazole (1)
Pfizer (7) · Nitric BioTherapeutics, Inc (4) · DermBiont, Inc. (3) · Hallux, Inc. (2) · Nomir Medical Technologies (2) · Sun Pharmaceutical Industries, Inc. (2) · Topica Pharmaceuticals (2) · Viamet (2) · 9305-9954 Quebec Inc (1) · Abeona Therapeutics, Inc (1) · Almirall, S.A. (1) · AmDerma (1) · AmtixBio Co., Ltd. (1) · Bayer (1) · Blueberry Therapeutics (1)
United States (34) · Canada (9) · Germany (4) · Mexico (4) · Brazil (2) · Dominican Republic (2) · Czechia (1) · Egypt (1) · Iceland (1) · India (1) · New Zealand (1) · Pakistan (1) · Philippines (1) · Poland (1) · Puerto Rico (1)
Phoebe Rich, MD (2) · Aditya Gupta, MD,PhD (1) · Alan Robbins, M.D. (1) · Alicia Barba, MD (1) · Alicia Bucko, DO (1) · Bernard Goffe, MD (1) · Boni Elewski, MD (1) · Brock McConnehey,, DO (1) · Carl Schanbacher, MD (1) · Charles Lynde, MD (1) · Christoph Willers, MD, MBA (1)
PMID 21967490, PMID 23377392, PMID 24173203, PMID 27297276, PMID 30526582, PMID 32421854, PMID 39624747
2008 (1), 2009 (1)